

Brii Biosciences Limited 腾盛博药生物科技有限公司

(A company incorporated in the Cayman Islands with limited liability)

(Stock Code: 2137)

Reply Form Brii Biosciences Limited (the "Company") (Stock Code: 2137) c/o Tricor Investor Services Limited 17/F, Far East Finance Centre 16 Harcourt Road, Hong Kong I/We would like to receive the future Corporate Communications# of the Company in the manner as indicated below: (Please mark a "\(\sigma\)" in **ONLY ONE** of the following boxes) to access all future Corporate Communications by electronic means through the Company's website (the "Website Version") instead of receiving printed copies, and receive an email notification to my/our email address below or a notification letter of the publication of the Corporate Communications on the Company's website; OR (Please provide the email address in English Capital Letters and the email address will be used for email notification of the release of the Corporate Communications only. If no email address is provided, a printed notification letter of the posting of Corporate Communications on the website of the Company will be sent to you by post at your address as appearing in the Company's register of members.) to receive the printed English version of all future Corporate Communications ONLY: OR to receive the printed Chinese version of all future Corporate Communications ONLY; OR to receive both the printed English and Chinese versions of all future Corporate Communications. Signature:

The above instruction will apply to all future Corporate Communications to be sent to you until you notify otherwise the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, by reasonable notice in writing to 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong or by email to britibio-ecom@hk.tricorglobal.com.

You are entitled at any time by reasonable notice in writing to the Company's branch share registrar and transfer office in Hong Kong to change your choice of means of receipt and/or language of future

To a restricted a large time of any time by reasonable notice in writing to the Company's staticn shall registrat and transfer of the information of the information.

For the avoidance of doubt, the Company does not accept any special instructions written on this Reply Form.

Corporate Communication(s) refer to any document issued or to be issued by the Company for the information or action of holders of any of the Company's securities, including but not limited to: (a) directors' reports, annual accounts together with the auditors' reports and, where applicable, summary interim reports; (c) notices of meetings; (d) listing documents; (e) circulars; (f) proxy forms; and (g) reply slips.

Please complete all your details clearly. Any Reply Form that has not been completed clearly or otherwise incorrectly completed will be void at the discretion of the Company.

By selecting to receive the Website Version of the Corporate Communications instead of receiving printed copies, you have expressly consented to waive the right to receive the Corporate Communications in printed form.

If the Company does not receive this reply form from you by May 26, 2023, you are deemed to have consented to receive the Company's Corporate Communications on the Company's website. Therefore, the Company will send you a notification letter of the publication of the Corporate Communications on the Company's website and you can read all future Corporate Communications via the Website

If your shares are held in joint names, the shareholder whose name stands first on the register of members of the Company in respect of the joint holding should sign on this Reply Form in order to be

PERSONAL INFORMATION COLLECTION STATEMENT

"Personal Data" in this statement has the same meaning as "personal data" defined in the Personal Data (Privacy) Ordinance, Cap. 486 (the "PDPO"), which may include but not limited to your name, contact telephone number, email address and mailing address

Your supply of Personal Data is on a voluntary basis for the purpose of receiving Corporate Communications in the manner chosen. Your Personal Data will be retained for such period as may be necessary for our verification and record purposes.

You have the right to request access to and/or correction of the respective Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of the Personal Data should be in writing by either of the following means:

Privacy Compliance Officer By mail to:

Contact telephone number:

Tricor Investor Services Limited 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong

By email to: is-enquiries@hk.tricorglobal.com

(Please cut along the dotted line. 請沿虛線剪下。)

Date:

Mailing Label 郵寄標籤

Tricor Investor Services Limited 卓佳證券登記有限公司 Freepost No. 簡便回郵號碼:10 GPO Hong Kong 香港 Brii Bio (2137)

Please cut the mailing label and stick this on an envelope

to return the Reply Form to us No postage stamp is required for local mailing 閣下寄回此回條時,請將此郵寄標籤剪貼於信封上 如在本港投寄, 閣下無需支付郵費或貼上郵票

% ------